Inter- and intra-observer variability in the measurement of length at endoscopy: Implications for the measurement of Barrett's esophagus

Gastrointestinal Endoscopy

Volumn 59, Issue 6, 2004, Pages 655-658

  Guda, Nalini M ^a,b   Partington, Susan ^a,b   Vakil, Nimish ^a,b,c  

^a Univ of Wisconsin Medical School ^*

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c AURORA SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CLINICAL PRACTICE; ESOPHAGOSCOPY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OBSERVER VARIATION; PHYSICAL MODEL; PRIORITY JOURNAL;

BARRETT ESOPHAGUS; CLINICAL COMPETENCE; ENDOTHELIUM; ESOPHAGUS; HUMANS; MODELS, STRUCTURAL; OBSERVER VARIATION;

EID: 2342661253     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5107(04)00182-8     Document Type: Article

References (14)

1. Deviere J, Buset M, Dumonceau JM, Rickaert F, Cremer M. Regression of Barrett's epithelium with omeprazole. N Engl J Med 1989;320:1497-8.
2. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998;12:893-7.
3. Gore S, Healey CJ, Sutton R, Eyre-Brook LA, Gear MW, Shepherd NA, et al. Regression of columnar-lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
4. Malesci A, Savarino V, Zentilin P, Belicchi M, Mela GS, Lapertosa G, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-5.
5. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94.
6. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
7. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-9.
8. Iftikhar S, James P, Steele R, Hardcastle J, Atkinson M. Length of Barrett's esophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
9. Sonnenberg A, Giger M, Kern L, Noll C, Study K, Weber KB, et al. How reliable is determination of ulcer size by endoscopy? Br Med J 1979;2:1322-4.
10. Vakil N, Smith W, Bourgeois K, Everbach EC, Knyrim K. Endoscopic measurement of lesion size: improved accuracy with image processing. Gastrointest Endosc 1994;40:178-83.
11. Landis RJ, Koch GO. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
12. Kim R, Baggott BB, Rose S, Shar AO, Mallory DL, Lasky SS, et al. Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology 1995;108:360-6.
13. Eisen GM, Montgomery EA, Azumi N, Hartmann DP, Bhargava P, Lippman M, et al. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials. Gastrointest Endosc 1999;50:814-8.
14. Sampliner RE. Detecting, measuring, and managing Barrett's esophagus: the complete endoscopist's dilemma. Gastrointest Endosc 1997;45:533-5.